| ATPC 0.1085 55.00% | MTEN 0.0341 -3.40% | OCG 0.01 -15.25% | SOXS 2.1449 -5.93% | AUID 1.87 88.41% | ZSL 2.9224 3.82% | CJMB 3.8899 247.31% | IVP 0.049 -40.24% | NVDA 187.1718 2.20% | SLV 83.375 -1.40% | ASST 0.9713 -5.70% | BBAI 6.285 0.40% | INTC 48.6734 -0.10% | SPHL 23.245 933.11% | DVLT 0.7323 1.96% | TZA 5.965 -3.17% | ONDS 13 -4.13% | GRAB 4.355 -5.94% | TQQQ 54.3 0.87% | BYND 1.0151 5.53% | SOXL 58.99 6.52% | BNKK 4.1 47.48% | NVD 7.095 -4.25% | DNN 3.545 1.72% | APLT 0.1003 0.40% | PTHL 0.8008 82.08% | PLUG 2.275 -3.19% | IBRX 3.9107 29.49% | DUST 5.755 -0.69% | AAL 15.68 3.57% | BITO 13.2128 -2.56% | SPY 691.71002 0.20% | TSLS 5.205 0.29% | TSLL 17.9686 -0.56% | EEM 58.0992 0.60% | MSTX 4.8291 -7.13% | FNGD 5.54 0.54% | ACHR 8.9322 0.25% | AMD 228.895 2.37% | QQQ 621.40302 0.30% | SIDU 3.72 -0.80% | IBIT 54.0499 -2.51% | NOK 6.615 4.01% | JDST 2.0837 -1.01% | TSLA 438.17001 -0.23% | RZLV 4.6464 14.44% | GPUS 0.2815 -12.28% | SOFI 26.35 -1.20% | MARA 10.7746 -3.02% | XLE 47.67 -0.81%

Raymond James Downgrades Haemonetics To Outperform, Cuts Price Target To $78

Raymond James downgraded Haemonetics (NYSE:HAE) from Strong Buy to Outperform and reduced its price target to $78 from $105 following softer performance in its interventional technologies unit.

The firm cited a slowdown in vascular closure in the EP market, with growth of 6% year-over-year versus 28% in the prior quarter. Analysts attributed the decline to execution issues rather than increased competition, but noted uncertainty over the timing of improvement.

Despite the downgrade, Raymond James said it still views Haemonetics as an attractive, undervalued company with potential to return to mid-single-digit organic growth and expanding margins, supported by strong performance in plasma and blood management.

Published on: August 11, 2025